Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: AMRI | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: AMRI

Euticals acquisition boosts revenues

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AMRI
 
3Q Revenues: $152.7 million (+46%)

3Q Loss: $23.4 million (loss of $4.2 billion 3Q15)

YTD Revenues: $379.1 million (+37%)

YTD Loss: $54.8 million (loss of $4.1 million YTD15)

Comments: Contract revenue was $151.7 million in the quarter, up 50% primarily related to the acquisition of Euticals. Recurring royalty revenue in the quarter was $1.1 million, down from $3.2 million in 3Q15, reflecting a change in estimate of the second quarter royalties related to Allergan’s sales of mixed amphetamine salts. R&D expenses in the quarter were $4.6 million, up from $1.9 million in the third quarter 2015, reflecting increased investment in collaboration agreements and API portfolio.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters